Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,467.32 +2.70 (+0.05%) Dow
39,359.25 +208.92 (+0.53%) Nasdaq
17,632.06 -57.30 (-0.32%) Bitcoin USD
61,239.42 -3,006.76 (-4.68%) CMC Crypto 200
1,267.50 -42.22 (-3.23%)
Cocrystal Pharma Inc (8CC.SG)
| Previous close | 2.3000 |
| Open | 2.4400 |
| Bid | 2.4800 x N/A |
| Ask | 2.6400 x N/A |
| Day's range | 2.4400 - 2.4400 |
| 52-week range | 1.2400 - 2.8200 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireNew Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies. CC-42344 is a new class of antiviral drugs designed to block essential steps in the replication and transcription of the influenza A virus. Cocrystal is conducting an influenza A Phase 2a clini
ZacksCocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- GlobeNewswire
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected in the second half of 2024FDA pre-IND feedback for oral CC-42344 received in first quarter of 2024 provides better clarity on late-stage trial designInitiation of Phase 1 study of inhaled CC-42344, a potential i
